Neoplastic Process – Page 55

FDA Approves AstraZeneca’s Imfinzi for Use Before and After Lung Cancer Surgery

1 year ago talkbio0Tagged Approved, AstraZeneca, durvalumab, Imfinzi, Immunologic Adjuvants, Malignant neoplasm of lung, Neoadjuvant Therapy, Non-Small Cell Lung Carcinoma, Surgery specialty, United States Food and Drug Administration

FDA approval, AstraZeneca, Imfinzi, lung cancer, surgery, neoadjuvant, adjuvant, durvalumab, NSCLC

England’s NICE Approves Theramex’s Uterine Fibroids Treatment

1 year ago talkbio0Tagged Antagonist muscle action, gonadorelin, hormonal add-back therapy, linzagolix, Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Theramex, Uterine Fibroids, women 's, Yselty

NICE, Theramex, uterine fibroids, linzagolix, Yselty, GnRH antagonist, hormonal add-back therapy, NHS, women’s health

FDA Approval of Amgen’s Imdelltra for Lung Cancer Amidst Challenges and Market Competition

1 year ago talkbio0Tagged Adverse event, amgen, Approved, bispecific T-cell, Curon, Imdelltra, Legend, Malignant neoplasm of lung, United States Food and Drug Administration

Amgen, Imdelltra, FDA approval, lung cancer, bispecific T-cell engager, adverse events, Merck, Curon, Legend Biotech

Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma

1 year ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, expansion, Incyte, Labels (device), Lymphoma, Follicular, Monjuvi, MorphoSys, Phase 3 Clinical Trials, tafasitamab, United States Food and Drug Administration

Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.

Grail Lays Off About 350 Employees, Puts Brakes on New Hires

1 year ago talkbio0Tagged cost-cutting measures, Detection, Galleri test, Grail, Illumina, Malignant Neoplasms, restructuring

Grail, layoffs, restructuring, biotech, cancer detection, Galleri test, Illumina, workforce reduction, cost-cutting measures

AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

1 year ago talkbio0Tagged Approved, AstraZeneca, Combined Modality Therapy, EU, Imfinzi, Immunotherapy, Inhibitor, Lynparza, Malignant neoplasm of endometrium, Mismatch Repair, Mismatch Repair Deficiency, PARP1 gene, proficient

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient

Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)

1 year ago talkbio0Tagged Agonist, azacitidine, Clinical Trials, Futility Analysis, Leukemia, Myelocytic, Acute, RARα, SELECT-AML-1, Syros Pharmaceuticals, tamibarotene, venetoclax

Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis

Halda Therapeutics Secures $126M to Advance ‘Hold and Kill’ Solid Tumor Drugs into Clinical Trials

1 year ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, Halda, Malignant neoplasm of breast, Malignant neoplasm of prostate, RIPTAC, Series B extension financing, Solid Neoplasm

Halda Therapeutics, RIPTAC therapeutics, cancer treatment, solid tumors, prostate cancer, breast cancer, clinical trials, Series B extension financing